• Laniush F. V. Danylo Halytsky National Medical University, Lviv, Ukraine
  • Urbanovych A. M. Danylo Halytsky National Medical University, Lviv, Ukraine



type 2 diabetes, eating disorders, leptin, ghrelin, adiponectin


This review analyzes the impact of eating disorders on type 2 diabetes mellitus. The most common types of eating disorders among people suffering from diabetes are binge eating and night-eating syndrome. They are accompanied by excessive intake of food and worsen the course of type 2 diabetes: make it difficult to reach the target levels of glycemia and lipidogram, normalization of body weight. Lifestyle change, namely diet and exercise, is one of the main treatments for diabetes. However, in the presence of the eating disorders adherence to dietary recommendations becomes a difficult task for this category of patients. In addition, there is a large percentage of patients with binge eating and night-eating syndrome who are not aware of their problem and are not trying to change their own lifestyle, which hinders treatment of the main disease - type 2 diabetes. The main regulators of eating behavior in humans are leptin and ghrelin. By binding to the receptors of the center of hunger and satiety located in the hypothalamus, these hormone-like substances affect the frequency of food intake and control the body's energy balance. Leptin has orexogenic properties; it forms a sense of satiety in the body. However, in patients with obesity and diabetes its level is increased due to the development of leptin resistance. In turn, ghrelin has the opposite properties: it creates a feeling of hunger. Its concentration in obese and diabetic people remains low compared to healthy individuals. According to scientific literature, the levels of leptin and ghrelin in patients with obesity, type 2 diabetes and eating disorders are different from healthy individuals. However, their role in the formation of eating habits and disorders is still poorly understood. Further studies are needed to determine the effectiveness of determining leptin and ghrelin levels in patients with type 2 diabetes to predict the development of eating disorders. It is assumed that the timely treatment of eating disorders will quickly achieve sustained compensation for the underlying disease, targeted levels of glycemia and lipidogram, normalization of body weight, which will reduce cardiovascular risk in patients with type 2 diabetes. The active study of the influence of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on appetite regulation is one of the priority directions of modern diabetology.


IDF. Diabetes Atlas. 8th Edition. 2017.

NCD Risk Factor Collaboration (NCD-RisC). Lancet 2016; 387: 1377-1396.

Wing RR, Jeffery RW. Int J Obes Related Metab Dis 1995; 19(1): 67-73.

Calvert M, Shankar A, McManus RJ, et al. Brit Med J 2009; 338(7707): 1366-1370.

Sharma A, Green JB, Dunning A, et al. Diabetes Care 2017; 40(12):1763-1770.

Centers for Disease Control and Prevention. National diabetes statistics report, Atlanta, 2017.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders : DSM-5. 2013.

Selime Зelik, Yusuf Kayar, Rabia Цnem Akзakaya, et al. Gen Hosp Psychiatry 2015; 37(2): 116-119.

Gallant AR, Lundgren J, Drapeau V. Obesity Rev 2012; 13(6): 528-536.

Kessler RC, Berglund PA, Chiu WT, et al. Biological Psychiatry 2013; 73(9): 904-914.

Nicolau J, Simo R, Sanchis P, et al. Acta Diabetol 2015; 52(6): 1037-1044.

Wing RR, Marcus MD, Epstein LH, et al. Int J Eating Dis 1989; 8: 671-679.;2-5.

Crow S, Kendall D, Praus B, Thuras P. Int J Eating Dis 2001; 30: 222-226.

Kenardy J, Mensch M, Bowen K, et al. Eating Behavior 2001; 2: 183-192.

Herpertz S, Albus C, Lichtblau K, et al. Int J Eating Dis 2000; 28: 68-77.<68:aid-eat8>;2-r.

De Zwaan M, Marschollek M, Allison KC. Eur Eating Dis Rev 2015.

Hilbert A, Pike KM, Goldschmidt AB, et al. Psychiatry Res 2014; 220: 500-506.

Allison KC, Lundgren JD, O’Reardon JP, et al. Int J Eating Dis 2010; 43(3): 241-217.

De Zwaan M, Muller A, Allison KC, et al. PLoS One 2014; 9(5): e97667.

Ceru-Bjork C, Andersson I, Rossner S. Int J Obes 2001; 25(3): 365-372.

Nieto-Martinez R, Gonzalez-Rivas JP, Medina-Inojosa JR, Florez H. Currence Diabetes Report 2017; 17(12): 138.

Wilfley Denise E, et al. Arch General Psychiatry 2002; 59(8): 713-721.

Telch Christy F, Stewart Agras W, Marsha M. Linehan. J Consulting Clin Psychology 2001; 69(6): 1061.

Vilsbull Tina, et al. BMJ 2012; 344: d7771.

Ribola FA, et al. Eur Rev Med Pharmacol Sci 2 017; 21(1): 199-211.

Mechanick JI, Zhao S, Garvey WT. Global Heart 2017.

Urbanovych AM. Endokrynologija 2013; 18(1): 69-72.

Urbanovych AM. Probl Endokryn Patologii' 2013; 4: 25-30.

Niki Katsiki, Dimitri P.Mikhailidis, Maciej Banach. Acta Pharmacol Sin.2018; 39(7): 1176-1188.

Mankovsky B, Urbanovych A. Fiziolohichnyĭ zhurnal 2014; 60(4): 56-60.

Adami GF, Campostano A, Cella F, Scopinaro N. Int J Obes 2002; 26(8): 1125-1128.

Monteleone P, Di Lieto A, Tortorella A, et. al. Psychiatry Res 2 000; 9 4(2): 1 21-129.

Kopp W, Blum WF, Ziegler A, et al. Hormones and Metabolism 1 998; 3 0(5): 2 72-275.

Jimerson DC, Wolfe BE, Carroll DP, Keel PK. Int J Eating Dis 2010; 43(7): 584-588.

D'Amore A, Massignan C, Montera P, et. al. Int J Obes 2001; 25(3): 373-377.

Rachel Miller, Marian Tanofsky-Kraff, Lauren B. Shomaker, et al. Int J Obes 2014; 38(3): 397-403.

Imbeault P, Doucet E, Mauriege P, et al. Clin Sci (London) 2001; 101: 359-365.

Nakazato M, Murakami N, Date Y, et al. Nature 2001; 409: 194-198.

Kojima M, Hosoda H, Date Y, et al. Nature 1999; 378(402): 656-660.

Jerlhag E. Addiction Biology 2008; 13: 358-363.

Jerlhag E, Egecioglu E, Dickson SL, et al. Addiction Biology 2006; 11: 45-54.

Jerlhag E, Egecioglu E, Dickson SL, et al. Addiction Biology 2007; 12: 6-16.

Panagopoulos VN, Ralevski E. Psychopharmacology (Berlin) 2014; 231: 2725-2740.

Abizaid A, Liu Z-W, Andrews ZB, et al. J Clin Invest 2006; 116: 3229-3239.

Skibicka KP, Shirazi RH, Rabasa-Papio C, et al. Neuropharmacology

; 73: 274-283.

Waxman SE. Eur Eating Dis Rev 2 009; 1 7: 4 08-425.

Shiiya T, Nakazato M, Mizuta M, et al. J Clin Endocrinol Metab 2002; 87: 240-244.

Soriano-Guilleґn L, Barrios V, Campos-Barros A, Argente J. J Pediatrics 2004; 144: 36-42.

TschoЁp M, Weyer C, Tataranni PA, et al. Diabetes 2001; 50: 707-709.

Monteleone P, Fabrazzo M, Tortorella A, et al. Psychoneuroendocrinology 2005; 30: 243-250.

Iceta S, et al. Diab Metab 2018.

Dominica Hernandez, Nandini Mehta, Allan Geliebter. Obesity 2019; 27: 629-635.

Matsubara M, Maruoka S, Katayose S. Eur J Endocrinol 2002; 147: 173-180.

Lindsay RS, Funahashi T, Hanson RL, et al. Lancet 2002; 360: 57-58.

Deepa SS, Dong LQ. Am J P hysiol E ndocrinol M etab 2009; 296: E22-E36.

Bou Khalil, Hachem REl, Eating C. W eight D isorders 2014; 19: 3.




How to Cite

Laniush, F. V., & Urbanovych, A. M. (2020). EATING DISORDERS IN PATIENTS WITH TYPE 2 DIABETES. Problems of Endocrine Pathology, 73(3), 119-125.